The article presents the recommendations of an international task force on treating rheumatoid arthritis (RA) to achieve optimal therapeutic outcomes. The task force, comprising rheumatologists and patients, developed these recommendations based on a systematic literature review and expert opinion. The recommendations aim to guide patients, rheumatologists, and other stakeholders in achieving remission or low disease activity (LDA) as primary treatment goals. Key points include: 1. **Treatment Goals**: The primary goal is to maximize long-term health-related quality of life through symptom control, prevention of structural damage, normalization of function, and social participation. 2. **Remission as the Ultimate Goal**: Remission is defined as the absence of significant inflammatory disease activity, with LDA as an acceptable alternative for long-standing disease. 3. **Regular Follow-Up**: Treatment should be adjusted every 1-3 months during active disease, with follow-up examinations using composite measures of disease activity, including joint counts. 4. **Composite Measures**: Use of validated composite measures of disease activity, which include joint assessments, is essential for guiding treatment decisions. 5. **Sustained Remission**: Once achieved, the desired treatment target should be maintained throughout the course of the disease. 6. **Patient Involvement**: Patients must be appropriately informed about the treatment target and the strategy to reach it under the supervision of the rheumatologist. The recommendations are based on evidence and expert opinion, with high levels of agreement among the experts. They emphasize the importance of shared decision-making, regular follow-up, and the use of composite measures to guide treatment strategies.The article presents the recommendations of an international task force on treating rheumatoid arthritis (RA) to achieve optimal therapeutic outcomes. The task force, comprising rheumatologists and patients, developed these recommendations based on a systematic literature review and expert opinion. The recommendations aim to guide patients, rheumatologists, and other stakeholders in achieving remission or low disease activity (LDA) as primary treatment goals. Key points include: 1. **Treatment Goals**: The primary goal is to maximize long-term health-related quality of life through symptom control, prevention of structural damage, normalization of function, and social participation. 2. **Remission as the Ultimate Goal**: Remission is defined as the absence of significant inflammatory disease activity, with LDA as an acceptable alternative for long-standing disease. 3. **Regular Follow-Up**: Treatment should be adjusted every 1-3 months during active disease, with follow-up examinations using composite measures of disease activity, including joint counts. 4. **Composite Measures**: Use of validated composite measures of disease activity, which include joint assessments, is essential for guiding treatment decisions. 5. **Sustained Remission**: Once achieved, the desired treatment target should be maintained throughout the course of the disease. 6. **Patient Involvement**: Patients must be appropriately informed about the treatment target and the strategy to reach it under the supervision of the rheumatologist. The recommendations are based on evidence and expert opinion, with high levels of agreement among the experts. They emphasize the importance of shared decision-making, regular follow-up, and the use of composite measures to guide treatment strategies.